26,521 Shares in ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) Purchased by Russell Investments Group Ltd.

Russell Investments Group Ltd. acquired a new position in ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 26,521 shares of the biotechnology company’s stock, valued at approximately $114,000.

Other institutional investors have also recently bought and sold shares of the company. Aperio Group LLC purchased a new position in shares of ZIOPHARM Oncology during the second quarter valued at approximately $35,000. Coastal Investment Advisors Inc. boosted its holdings in ZIOPHARM Oncology by 427.5% during the 3rd quarter. Coastal Investment Advisors Inc. now owns 10,550 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 8,550 shares during the period. Cadence Capital Management LLC bought a new position in ZIOPHARM Oncology in the 3rd quarter valued at $61,000. Niemann Capital Management Inc. bought a new position in ZIOPHARM Oncology in the 2nd quarter valued at $79,000. Finally, Prudential Financial Inc. increased its stake in ZIOPHARM Oncology by 18.8% in the second quarter. Prudential Financial Inc. now owns 16,673 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 2,640 shares during the period. 45.65% of the stock is currently owned by institutional investors.

Shares of NASDAQ ZIOP opened at $5.09 on Friday. ZIOPHARM Oncology Inc. has a twelve month low of $1.56 and a twelve month high of $7.25. The firm has a market cap of $955.84 million, a PE ratio of -10.60 and a beta of 2.60. The business has a fifty day simple moving average of $4.51 and a two-hundred day simple moving average of $4.92. The company has a quick ratio of 10.34, a current ratio of 10.34 and a debt-to-equity ratio of 0.01.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.34). On average, research analysts expect that ZIOPHARM Oncology Inc. will post -0.33 earnings per share for the current year.

In related news, CAO Kevin G. Lafond sold 11,667 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $5.25, for a total value of $61,251.75. Following the completion of the sale, the chief accounting officer now directly owns 97,222 shares of the company’s stock, valued at $510,415.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 2.00% of the company’s stock.

A number of analysts have recently issued reports on the stock. ValuEngine lowered shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 2nd. Raymond James set a $6.50 price target on shares of ZIOPHARM Oncology and gave the stock an “outperform” rating in a research note on Monday, November 25th. HC Wainwright reiterated a “buy” rating and set a $6.50 price objective on shares of ZIOPHARM Oncology in a report on Wednesday, October 2nd. Zacks Investment Research lowered shares of ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, BidaskClub raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, October 29th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. ZIOPHARM Oncology has an average rating of “Hold” and a consensus price target of $6.65.

ZIOPHARM Oncology Profile

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

Read More: The limitations of an equal weight rating

Want to see what other hedge funds are holding ZIOP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZIOPHARM Oncology Inc. (NASDAQ:ZIOP).

Institutional Ownership by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit